Llovet, Josep M. http://orcid.org/0000-0003-0547-2667
Castet, Florian
Heikenwalder, Mathias
Maini, Mala K. http://orcid.org/0000-0001-6384-1462
Mazzaferro, Vincenzo
Pinato, David J.
Pikarsky, Eli http://orcid.org/0000-0003-4186-7105
Zhu, Andrew X.
Finn, Richard S.
Article History
Accepted: 11 October 2021
First Online: 11 November 2021
Competing interests
: J.M.L. has received research support from Bayer HealthCare, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Eisai and Ipsen, and consulting fees from AstraZeneca, Bayer HealthCare, BMS, Eisai, Eli Lilly, Exelixis, Genentech, Glycotest, Ipsen, Merck, Mina Alpha, Nucleix and Roche. M.K.M. is named co-inventor on international patent application No.1917498.6, entitled Treatment of Hepatitis B Virus (HBV) Infection, filed by UCL Business Ltd. M.K.M. has received unrestricted funding from Gilead, Immunocore and Roche, and advisory board/consulting fees from Abbvie, Freeline, Galapagos NV, Gilead, GlaxoSmithKline, Hoffmann La Roche, Immunocore and VIR. D.P. has received consulting fees from AstraZeneca, Bayer HealthCare, BMS, DaVolterra, Eisai, H3 Biomedicine, Ipsen, Mina Alpha, Roche and ViiV Healthcare, and research funding (to institution) from BMS and Merck Sharp & Dohme. The other authors declare no competing interests.